Dr Webb has had extensive experience in developing NCE’s from discovery, to registration and launch during a long career with GSK where he was Vice President of Development Chemistry and Analysis in the UK. He has presented and published externally and has edited 3 book on analytical chemistry.
Dr. Webb was responsible for setting up GSK’s approach to oligonucleotide development. Since his retirement from GSK, he has been consulting on the manufacturing, analysis and development of therapeutic oligonucleotides working on antisense, SiRNA, mRNA and splice therapeutics (including conjugates) with a number of biotechnology companies. Dr. Webb has extensive knowledge of the contract manufacturing market for oligonucleotides and the current regulatory landscape.